Screener
Spyre Therapeutics, Inc. SYRE Common Stock Par Value Per Share
Common Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 shares authorized as of March 31, 2026 and December 31, 2025; 346,045 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 146,425 | 146,425 |
| Series B non-voting convertible preferred stock, $0.0001 par value; 271,625 shares authorized and 16,667 shares issued and outstanding as of March 31, 2026 and December 31, 2025. | 9,395 | 9,395 |
| Preferred stock, $0.0001 par value; 8,642,034 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025. | — | — |
| Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 78,839,858 shares and 78,189,811 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 15 | 15 |
| Additional paid-in capital | 1,712,383 | 1,686,167 |
| Accumulated other comprehensive (loss) income | (767) | 869 |
| Accumulated deficit | (1,196,640) | (1,127,635) |
| TOTAL STOCKHOLDERS’ EQUITY | 670,811 | 715,236 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s common stock par value per share?
- Spyre Therapeutics, Inc. (SYRE) reported common stock par value per share of $0.00 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s common stock par value per share changed year-over-year?
- Spyre Therapeutics, Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Spyre Therapeutics, Inc.'s common stock par value per share?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does common stock par value per share mean?
- The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.
Ask your AI about Spyre Therapeutics, Inc.'s common stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude